Patients who experience adverse ocular effects with bisphosphonates have a notably higher risk for osteonecrosis than those who do not experience such events, a large cohort study shows.
CHICAGO — More than a third of women at very high risk for fracture from postmenopausal osteoporosis were not receiving treatment, and over half of those receiving treatment were taking oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback